<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wu J</submitter><funding>NICHD NIH HHS</funding><funding>NIDDK NIH HHS</funding><pagination>4274-4282</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5123794</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>197(11)</volume><pubmed_abstract>Discovery of immune tolerance mechanisms, which inhibit pre-existing autoimmune inflammation, may provide us with new strategies for treating autoimmune diseases. We have identified a CD8??+MHC class II+ cell with professional APC capacity during our investigation on spontaneous recovery from autoimmune glomerulonephritis in a rat model. This cell actively invades inflamed target tissue and further terminates an ongoing autoimmune inflammation by selective killing of effector autoreactive T cells. In this study, we show that this cell used a cytotoxic machinery of Ly49s+ NK cells in killing of target T cells. Thus, this CD8??+MHC class II+ cell was a dually functional Ag-presenting NK-like (AP-NK) cell. Following its coupling with target T cells through Ag presentation, killing stimulatory receptor Ly49s6 and coreceptor CD8?? on this cell used rat nonclassic MHC class I C/E16 on the target T cells as a ligand to initiate killing. Thus, activated effector T cells with elevated expression of rat nonclassic MHC class I C/E16 were highly susceptible to the killing by the CD8??+ AP-NK cell. Granule cytolytic perforin/granzyme C from this cell subsequently mediated cytotoxicity. Thus, inhibition of granzyme C effectively attenuated the killing. As it can recognize and eliminate effector autoreactive T cells in the inflamed target tissue, the CD8??+ AP-NK cell not only represents a new type of immune cell involved in immune tolerance, but it also is a potential candidate for developing a cell-based therapy for pre-existing autoimmune diseases.</pubmed_abstract><journal>Journal of immunology (Baltimore, Md. : 1950)</journal><pubmed_title>CD8??+MHC Class II+ Cell with the Capacity To Terminate Autoimmune Inflammation Is a Novel Antigen-Presenting NK-like Cell in Rats.</pubmed_title><pmcid>PMC5123794</pmcid><funding_grant_id>R01 DK060029</funding_grant_id><funding_grant_id>R01 HD049613</funding_grant_id><funding_grant_id>R01 DK077857</funding_grant_id><pubmed_authors>Wu J</pubmed_authors><pubmed_authors>Ross A</pubmed_authors><pubmed_authors>Carlock C</pubmed_authors><pubmed_authors>Lou Y</pubmed_authors><pubmed_authors>Shim J</pubmed_authors></additional><is_claimable>false</is_claimable><name>CD8??+MHC Class II+ Cell with the Capacity To Terminate Autoimmune Inflammation Is a Novel Antigen-Presenting NK-like Cell in Rats.</name><description>Discovery of immune tolerance mechanisms, which inhibit pre-existing autoimmune inflammation, may provide us with new strategies for treating autoimmune diseases. We have identified a CD8??+MHC class II+ cell with professional APC capacity during our investigation on spontaneous recovery from autoimmune glomerulonephritis in a rat model. This cell actively invades inflamed target tissue and further terminates an ongoing autoimmune inflammation by selective killing of effector autoreactive T cells. In this study, we show that this cell used a cytotoxic machinery of Ly49s+ NK cells in killing of target T cells. Thus, this CD8??+MHC class II+ cell was a dually functional Ag-presenting NK-like (AP-NK) cell. Following its coupling with target T cells through Ag presentation, killing stimulatory receptor Ly49s6 and coreceptor CD8?? on this cell used rat nonclassic MHC class I C/E16 on the target T cells as a ligand to initiate killing. Thus, activated effector T cells with elevated expression of rat nonclassic MHC class I C/E16 were highly susceptible to the killing by the CD8??+ AP-NK cell. Granule cytolytic perforin/granzyme C from this cell subsequently mediated cytotoxicity. Thus, inhibition of granzyme C effectively attenuated the killing. As it can recognize and eliminate effector autoreactive T cells in the inflamed target tissue, the CD8??+ AP-NK cell not only represents a new type of immune cell involved in immune tolerance, but it also is a potential candidate for developing a cell-based therapy for pre-existing autoimmune diseases.</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Dec</publication><modification>2020-11-19T15:00:00Z</modification><creation>2019-03-27T02:29:50Z</creation></dates><accession>S-EPMC5123794</accession><cross_references><pubmed>27799310</pubmed><doi>10.4049/jimmunol.1601207</doi></cross_references></HashMap>